Scientists at the McGovern Institute and the Broad Institute of MIT and Harvard have reengineered a compact RNA-guided enzyme they found in bacteria into an efficient, programmable editor of human DNA ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is ...

Growing focus on gene-based therapies, advances in editing tools, and increasing research investments are accelerating the adoption of genome editing technologies across life sciences and agriculture.

Genome editing technologies like CRISPR-Cas9 have transformed biology, medicine, and agriculture, but concerns remain about unintended edits at off-target DNA sites. These off-target effects can cause ...

The National Institutes of Health will launch a research program to encourage the development of genome-editing treatments for various diseases. Under the Somatic Cell Genome Editing program, the NIH ...

Recent scientific advances have made genome editing technologies—a suite of biological tools for making precise additions, deletions, and alterations to the DNA and RNA of living cells– more rapid, ...

Advancements in genome editing technologies the growing emphasis on safe and accurate gene correction, and strong biotechnology R&D investment drive the base editing market.Austin, Texas, Jan. 21, ...

Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells Metagenomi is a precision genetic medicines ...

Recent scientific advances have made genome editing technologies—a suite of biological tools for making precise additions, deletions, and alterations to the DNA and RNA of living cells– more rapid, ...

MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of ...